Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094832 | 0.85 | CYP2D6 (0.35) | HRH3CYP2D6KCNH2HSD11B1KMT2A | |
| SCHEMBL25818430 | 0.83 | HRH3 (0.41) | HRH3CYP2D6KCNH2HSD11B1KMT2A | |
| SCHEMBL22332273 | 0.82 | CYP2D6 (0.41) | HRH3CYP2D6KCNH2KMT2APAX8 | |
| SCHEMBL23178967 | 0.78 | CYP2D6 (0.40) | HRH3CYP2D6KCNH2HSD11B1KMT2A | |
| SCHEMBL21613836 | 0.78 | HRH3 (0.32) | HRH3 | |
| SCHEMBL17752563 | 0.78 | CYP2D6 (0.43) | HRH3CYP2D6KCNH2HSD11B1KMT2A | |
| SCHEMBL23168917 | 0.77 | CYP2D6 (0.37) | HRH3CYP2D6KCNH2KMT2APAX8 | |
| SCHEMBL8262509 | 0.77 | PHGDH (0.34) | HRH3KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL20247967 | 0.75 | SHBG (0.35) | HRH3CYP2D6KMT2ARAB9AMEN1 | |
| SCHEMBL13638195 | 0.75 | GNAI3 (0.41) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | HRH3 2355/4885CYP2D6 3502/4885KCNH2 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.